More than 2 million suffer from rheumatoid arthritis
A progressive disease often leading to chronic pain and severe, incapacitating disabilities, rheumatoid arthritis (RA)cause s the body’s immune system to inflame, destroying soft tissue and eroding bone and cartilage. The current treatment options for RA have potentially significant side effects and limitations.
Rigel's RA program is focused on the development of an oral disease modifying anti-rheumatic drug (DMARD) to be used early in the course of the disease.
Unlike current RA treatments, some of which are delivered by injection, fostamatinib (previously R788) reversibly blocks signaling in multiple cell types involved in inflammation and tissue degradation in RA. And because it is delivered orally, fostamatinib may help patients overcome treatment obstacles often encounte red with injectable drugs.
Planned for use in the early stages of the disease, fostamatinib will potentially diminish swelling and tissue destruction, preventing the progression to major bone and cartilage destruction.
RA suffers may have a chance to lead active, healthy lifestyles
- Immune Thrombocytopenic Purpura (ITP) is a blood disorder in which the immune system attacks and destroys platelets in the blood, resulting in an abnormally low platelet count. Rigel is focusing its ITP program on the chronic form of this disorder, targeting the underlying autoimmune cause of the disease, rather than stimulating platelet production.
- Approximately 200,000 people in the U.S. suffer from ITP. The majority of these cases are in women, with 50% of the new cases being found in children.
- Antibodies, usually of the IgG type, mediate the destruction in ITP. R788 has a novel mechanism of action, blocking IgG receptor signaling in macrophages and B-cells.